Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014		Mar. 31, 2013
Cash flows from operating activities:
Net loss	$ (45,091)		$ (34,762)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,564		3,429
Non-cash interest on 2033 Senior Notes	1,777		1,303
Amortization of deferred financing costs	177		145
Losses from investments in investees	2,056		3,890
Equity-based compensation – employees and non-employees	3,579		5,205
Provision for (recovery of) bad debts	(74)		381
Provision for inventory obsolescence	337		939
Revenue from receipt of equity	(60)		(12,540)
Realized gain on sale of equity securities	(1,273)		(2,347)
Change in fair value of derivatives instruments	10,515		23,549
Change in fair value of contingent consideration	2,610		1,344
Deferred income tax benefit	0		98
Changes in assets and liabilities, net of the effects of acquisitions:
Accounts receivable	(557)		(558)
Inventory	(1,676)		(1,439)
Prepaid expenses and other current assets	1,145		(2,570)
Other assets	1,429		71
Accounts payable	1,479		(103)
Foreign currency measurement	(976)		(340)
Accrued expenses	(8,007)		(440)
Net cash used in operating activities	(29,046)		(14,745)
Cash flows from investing activities:
Investments in investees	(500)		(2,500)
Proceeds from sale of equity securities	1,297		2,528
Acquisition of businesses, net of cash	(200)		78
Capital expenditures	(861)		(755)
Net cash provided by (used in) investing activities	(264)		(649)
Cash flows from financing activities:
Issuance of 2033 Senior Notes, net, including related parties	0		170,184
Payment of Series D dividends, including related parties	0		(3,015)
Proceeds from the exercise of Common Stock options and warrants	1,639		995
Borrowings on lines of credit	4,250		8,428
Repayments of lines of credit	(5,985)		(6,951)
Net cash provided by financing activities	(96)		169,641
Effect of exchange rate on cash and cash equivalents	4		(12)
Net (decrease) increase in cash and cash equivalents	(29,402)		154,235
Cash and cash equivalents at beginning of period	185,798	[1]	27,361
Cash and cash equivalents at end of period	156,396	[1]	181,596
SUPPLEMENTAL INFORMATION:
Interest paid	2,420		242
Income taxes paid (refunded), net	377		(118)
RXi common stock received	0		12,500
Pharmsynthez common stock received	6,264		0
Non-cash financing:
Series D Preferred Stock	0		24,386
Common Stock options and warrants, net exercised	657		815
Cytochroma [Member]
Issuance of Common Stock to acquire:
Stock Issued	0		146,902
OPKO Brazil [Member]
Issuance of Common Stock to acquire:
Stock Issued	0		436
Farmadiet [Member]
Issuance of Common Stock to acquire:
Stock Issued	$ 159		$ 0

[1] As of March 31, 2014 and December 31, 2013, total assets include $6.8 million and $6.7 million, respectively, and total liabilities include $11.4 million and $10.4 million, respectively, related to SciVac Ltd (“SciVac”), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.